Previous close | 42.94 |
Open | 43.26 |
Bid | 41.77 x 800 |
Ask | 41.78 x 800 |
Day's range | 41.17 - 43.40 |
52-week range | 32.69 - 48.82 |
Volume | |
Avg. volume | 1,010,041 |
Market cap | 5.974B |
Beta (5Y monthly) | 0.54 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.36 |
Earnings date | 07 Aug 2023 - 11 Aug 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 48.11 |
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 13% and 0.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Avalo Therapeutics, Inc. (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This drug candidate could be a great treatment option for patients with a potentially deadly disease.
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ionis (IONS) Q4 loss is narrower than expected. However, sales miss estimates. Revenue guidance for 2023 looks soft. Stock down.
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 65.09% and 3.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Relay Therapeutics, Inc. (RLAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Every investor in Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) should be aware of the most powerful shareholder groups...
Avita Medical Inc. (RCEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.
Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Ionis (IONS) incurs a narrower-than-expected loss in Q3. Its sales also beat estimates.
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 55.41% and 7.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ionis (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.